US3986510A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Bioerodible ocular device
Assignee: Alza Corp
•
Filing: 1975-08-01
•
Granted: 1976-10-19
•
Expires: 1995-08-01
Abstract
Abstract An ocular insert for the continuous controlled administration of a predetermined therapeutically effective dosage of drug to the eye over a prolonged period of time. The device meters the flow of drug by means of a drug release rate controlling material. The insert bioerodes in the environment of the eye concurrently with the dispensing or at a point in time after the dispensing of the therapeutically desired amount of drug.
Inventors
- 👤 Takeru Higuchi
- 👤 Anwar A. Hussain
- 👤 John W. Shell
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 10:15
CPC Classifications
A; A61; A61F; A61F9/00; A61F9/0008; A61F9/0017; A61K; A61K9/00; A61K9/0012; A61K9/0048; A61K9/0051
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
187 words
A bioerodible ocular device for the controlled continuous administration of a predetermined dosage of drug to the eye, comprising (1) an inner reservoir containing a drug formulation confined therein, and (2) an outer membrane formed from drug release rate controlling bioerodible material surrounding the inner reservoir, the membrane being permeable to passage of drug, but at a lower rate than through the inner reservoir, the device being of an initial shape which is adapted for insertion and retention in the sac of the eye bounded by the surfaces of the bulbar conjunctiva of the sclera of the eyeball and the palpebral conjunctiva of the lid, whereby release of drug from the device to the eye is effected primarily by a permeation control release mechanism in which the outer membrane continuously meters the flow of a therapeutically effective amount of drug from the reservoir to the eye at a controlled rate over a prolonged period of time, and wherein the device bioerodes in the environment of the eye concurrently with the dispensing or at a point in time after the dispensing of the therapeutically desired amount of drug.
Claim 2
Dependent Claim
187 words
A bioerodible ocular device for the controlled continuous administration of a predetermined dosage of drug to the eye, comprising (1) an inner reservoir containing a drug formulation confined therein, and (2) an outer membrane formed from drug release rate controlling bioerodible material surrounding the inner reservoir, the membrane being permeable to passage of drug, but at a lower rate than through the inner reservoir, the device being of an initial shape which is adapted for insertion and retention in the sac of the eye bounded by the surfaces of the bulbar conjunctiva of the sclera of the eyeball and the palpebral conjunctiva of the lid, whereby release of drug from the device to the eye is effected primarily by a permeation control release mechanism in which the outer membrane continuously meters the flow of a therapeutically effective amount of drug from the reservoir to the eye at a controlled rate over a prolonged period of time, and wherein the device bioerodes in the environment of the eye concurrently with the dispensing or at a point in time after the dispensing of the therapeutically desired amount of drug.
Claim 3
Dependent Claim
46 words
The ocular device defined by claim 1 wherein the outer membrane material has a release rate to drug and an erosion rate in the eye such that the drug is essentially depleted from the inner reservoir prior to the substantially complete bioerosion of the membrane material.
Claim 4
Dependent Claim
27 words
The ocular device defined by claim 1 wherein the drug permeation rate through the inner reservoir is at least twice the permeation rate through the outer membrane.
Claim 5
Dependent Claim
33 words
The ocular device defined by claim 1 wherein the inner reservoir comprises a matrix material selected from the group consisting of solid matrix materials and microporous matrix materials having the drug dispersed therethrough.
Claim 6
Dependent Claim
21 words
The ocular device defined by claim 1 wherein the inner reservoir comprises a hollow container having the drug formulation confined therein.
References Cited (Backward Citations)
US273410A
Cited
DE1003914B
Cited
US3113076A
Cited
US3297033A
Cited
US3249109A
Cited
US3329574A
Cited
US3444858A
Cited
US3574820A
Cited
US3598122A
Cited
US3598123A
Cited
US3598122B1
Cited
US3618604A
Cited
US3630200A
Cited
US3773919A
Cited
US3640741A
Cited
US3625214A
Cited
US3641237A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-10-19 | 1980-04-19 | 1980-10-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-10-19 | 1984-04-19 | 1984-10-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-10-19 | 1988-04-19 | 1988-10-19 | $7700.00 | Window Closed / Lapsed |